Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 5/20 | 0.58 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.58 |
| ▸ | ABL1 | P00519 | 7/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | IL2 | P60568 | 2/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449982 | 0.86 | IL2 (0.63) | ABCB1ABCC1ABL1IL2WNT3A | |
| SCHEMBL2310206 | 0.85 | DYRK1A (0.54) | ABCB1ABCC1ABL1DYRK1AIL2 | |
| SCHEMBL438951 | 0.82 | IL2 (0.56) | ABCB1ABCC1ABL1IL2WNT3A | |
| Hydrochloric Acid SCHEMBL450224 | 0.81 | IL2 (0.55) | ABCB1ABCC1ABL1IL2WNT3A | |
| SCHEMBL7933347 | 0.76 | ABCB1 (0.51) | ABCB1ABCC1DYRK1ADEGS1MAP3K5 | |
| SCHEMBL23405953 | 0.76 | DEGS1 (0.73) | ABCB1ABCC1DYRK1ADEGS1MKNK1 | |
| SCHEMBL29743850 | 0.76 | DEGS1 (0.73) | ABCB1ABCC1DYRK1ADEGS1MKNK1 | |
| SCHEMBL11911923 | 0.75 | IL2 (0.65) | IL2 | |
| SCHEMBL13838310 | 0.75 | IL2 (0.54) | ABCB1ABCC1ABL1IL2DEGS1 | |
| SCHEMBL2310680 | 0.74 | IL2 (0.54) | IL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | claimed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | claimed |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010039238-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196838-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | ABCB1 273/4885ABCC1 246/4885ABL1 3975/4885 |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | ABCB1 273/4885ABCC1 246/4885ABL1 3975/4885 |
| US-20140045861-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | ABCB1 273/4885ABCC1 246/4885ABL1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.